Match!
Timon Seeger
Stanford University
24Publications
10H-index
953Citations
Publications 24
Newest
#1Jaecheol LeeH-Index: 10
#2Vittavat Termglinchan (Cardiovascular Institute of the South)H-Index: 9
Last.Haodi Wu (Cardiovascular Institute of the South)H-Index: 18
view all 24 authors...
Lamin A/C (LMNA) is one of the most frequently mutated genes associated with dilated cardiomyopathy (DCM). DCM related to mutations in LMNA is a common inherited cardiomyopathy that is associated with systolic dysfunction and cardiac arrhythmias. Here we modelled the LMNA-related DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhyt...
#1Timon Seeger (Stanford University)H-Index: 10
#2Rajani Shrestha (Stanford University)H-Index: 3
Last.Matthew Greenhaw (Stanford University)H-Index: 1
view all 19 authors...
Background: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 (MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of ...
#1Jes-Niels Boeckel (Goethe University Frankfurt)H-Index: 8
#2Maya F. Perret (Goethe University Frankfurt)H-Index: 1
Last.Hugo A. KatusH-Index: 92
view all 23 authors...
Abstract Aims Circulating immune cells have a significant impact on progression and outcome of heart failure. Long non-coding RNAs (lncRNAs) comprise novel epigenetic regulators which control cardiovascular diseases and inflammatory disorders. We aimed to identify lncRNAs regulated in circulating immune cells of the blood of heart failure patients. Methods and results Next-generation sequencing revealed 110 potentially non-coding RNA transcripts differentially expressed in peripheral blood monon...
#1Alex C.Y. Chang (Stanford University)H-Index: 9
#2Andrew H. Chang (Stanford University)H-Index: 5
Last.Timon Seeger (Stanford University)H-Index: 10
view all 18 authors...
This study demonstrates that significantly shortened telomeres are a hallmark of cardiomyocytes (CMs) from individuals with end-stage hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) as a result of heritable defects in cardiac proteins critical to contractile function. Positioned at the ends of chromosomes, telomeres are DNA repeats that serve as protective caps that shorten with each cell division, a marker of aging. CMs are a known exception in which telomeres remain relativel...
#1Timon SeegerH-Index: 10
#2Caressa ChenH-Index: 2
Last.Joseph C. WuH-Index: 87
view all 4 authors...
#1Caressa Chen (Stanford University)H-Index: 2
#2Timon Seeger (Stanford University)H-Index: 10
Last.Ioannis Karakikes (Stanford University)H-Index: 26
view all 4 authors...
#1Haodi WuH-Index: 18
#2Huaxiao YangH-Index: 9
Last.Joseph C. WuH-Index: 87
view all 9 authors...
Background: Diastolic dysfunction is commonly seen in hypertrophic cardiomyopathy (HCM). However, the cellular mechanism is not fully understood, and no effective treatment so far has been developed. We hypothesize here that HCM patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) can recapitulate the cellular mechanism, and provide us a platform for mechanistic study and for drug screening of diastolic dysfunctions in HCM. Methods and Results: We generated beating iP...
#1Ioannis Karakikes (Stanford University)H-Index: 26
#2Vittavat Termglinchan (Stanford University)H-Index: 9
Last.Haodi Wu (Stanford University)H-Index: 18
view all 19 authors...
Rationale: Targeted genetic engineering using programmable nucleases such as transcription activator–like effector nucleases (TALENs) is a valuable tool for precise, site-specific genetic modification in the human genome. Objective: The emergence of novel technologies such as human induced pluripotent stem cells (iPSCs) and nuclease-mediated genome editing represent a unique opportunity for studying cardiovascular diseases in vitro. Methods and Results: By incorporating extensive literature and ...
#1Timon SeegerH-Index: 10
#2Matthew H. PorteusH-Index: 44
Last.Joseph C. WuH-Index: 87
view all 3 authors...
Genome editing has emerged as a powerful tool in research and is entering the stage of therapeutic applications. In the cardiovascular field, its role in basic and translational research is well established. However, biological and technical barriers currently hamper the therapeutic potential of genome editing for cardiovascular diseases. This viewpoint discusses possible routes for promoting therapeutic use of genome editing in the cardiovascular system. Genome editing has rapidly emerged as a ...
#1Vittavat Termglinchan (Stanford University)H-Index: 9
#2Timon Seeger (Stanford University)H-Index: 10
Last.Ioannis Karakikes (Stanford University)H-Index: 26
view all 5 authors...
123